BALCHEM CORP — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Balchem Corporation reported Q3 2026 net sales of $290.7M (up 8.6% YoY), net earnings of $46.7M (up 16.0%), and adjusted EBITDA of $80.3M (up 12.4%). All three segments—Human Nutrition & Health ($188.2M sales, +8.1%), Animal Nutrition & Health ($63.0M, +11.7%), and Specialty Products ($37.3M, +4.5%)—showed sales growth. The company repurchased $28M stock in Q3 and $127M over trailing twelve months, with net debt of $57.7M and leverage ratio of 0.2x. Gross margin improved 70 basis points to 36.4%, driven by sales growth, favorable mix, and manufacturing efficiencies.
Why this rating
Solid operational performance across all segments with healthy YoY growth (8–12%), margin expansion, and strong cash generation. At $5.1B market cap, Q3 sales of $290.7M and earnings of $46.7M represent normal quarterly business execution. No material M&A, guidance shift, or business disruption. Routine earnings beat is positive but not trajectory-altering for a company of this scale.
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.